Human cytomegalovirus pp71 stimulates major histocompatibility complex class I presentation of IE1-derived peptides at immediate early times of infection

Journal of Virology

Volumn 87, Issue 9, 2013, Pages 5229-5238

  Hesse, Julia ^a   Reyda, Sabine ^a   Tenzer, Stefan ^a   Besold, Katrin ^a,c   Reuter, Nina ^a   Krauter, Steffi ^a   Büscher, Nicole ^a   Stamminger, Thomas ^b   Plachter, Bodo ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMEDIATE EARLY PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PP71 PROTEIN; PP86 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIGEN PRESENTATION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DNA MODIFICATION; DNA PACKAGING; DOWN REGULATION; GENE DELETION; GENE DOSAGE; HUMAN; HUMAN CELL; LIMIT OF DETECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; OPEN READING FRAME; PP65 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA TRANSLATION; UPREGULATION; VIRION; VIRUS GENE; VIRUS GENOME; VIRUS MUTANT; VIRUS PARTICLE;

ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMEDIATE-EARLY PROTEINS; PEPTIDES; UP-REGULATION; VIRAL PROTEINS;

HUMAN HERPESVIRUS 5;

EID: 84876311577     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03484-12     Document Type: Article

References (58)

1. Powers C, DeFilippis V, Malouli D, Früh K. 2008. Cytomegalovirus immune evasion. Curr. Top. Microbiol. Immunol. 325:333-360.
2. Reddehase MJ. 2002. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat. Rev. Immunol. 2:831- 844.
3. Roy CR, Mocarski ES. 2007. Pathogen subversion of cell-intrinsic innate immunity. Nat. Immunol. 8:1179 -1187.
4. Tavalai N, Stamminger T. 2011. Intrinsic cellular defense mechanisms targeting human cytomegalovirus. Virus Res. 157:128 -133.
5. Reddehase MJ, Mutter W, Münch K, Bühring HJ, Koszinowski UH. 1987. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J. Virol. 61:3102-3108.
6. Steffens HP, Kurz S, Holtappels R, Reddehase MJ. 1998. Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. J. Virol. 72:1797-1804.
7. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038 -1044.
8. Besold K, Frankenberg N, Pepperl-Klindworth S, Kuball J, Theobald M, Hahn G, Plachter B. 2007. Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2-11- mediated immune evasion. J. Gen. Virol. 88:1429 -1439.
9. Besold K, Wills M, Plachter B. 2009. Immune evasion proteins gpUS2 and gpUS11 of human cytomegalovirus incompletely protect infected cells from CD8 T cell recognition. Virology 391:5-19.
10. Jones TR, Hanson LK, Sun L, Slater JS, Stenberg RM, Campbell AE. 1995. Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J. Virol. 69:4830-4841.
11. Liu Z, Winkler M, Biegalke B. 2009. Human cytomegalovirus: host immune modulation by the viral US3 gene. Int. J. Biochem. Cell Biol. 41:503-506.
12. Hansen SG, Powers CJ, Richards R, Ventura AB, Ford JC, Siess D, Axthelm MK, Nelson JA, Jarvis MA, Picker LJ, Fruh K. 2010. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328:102-106.
13. Gilbert MJ, Riddell SR, Plachter B, Greenberg PD. 1996. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate- early gene product. Nature 383:720 -722.
14. Trgovcich J, Cebulla C, Zimmerman P, Sedmak DD. 2006. Human cytomegalovirus protein pp71 disrupts major histocompatibility complex class I cell surface expression. J. Virol. 80:951-963.
15. Bresnahan WA, Shenk TE. 2000. UL82 virion protein activates expression of immediate early viral genes in human cytomegalovirus-infected cells. Proc. Natl. Acad. Sci. U. S. A. 97:14506 -14511.
16. Liu B, Stinski MF. 1992. Human cytomegalovirus contains a tegument protein that enhances transcription from promoters with upstream ATF and AP-1 cis-acting elements. J. Virol. 66:4434-4444.
17. Saffert RT, Kalejta RF. 2006. Inactivating a cellular intrinsic immune defense mediated by Daxx is the mechanism through which the human cytomegalovirus pp71 protein stimulates viral immediate-early gene expression. J. Virol. 80:3863-3871.
18. Schierling K, Stamminger T, Mertens T, Winkler M. 2004. Human cytomegalovirus tegument proteins ppUL82 (pp71) and ppUL35 interact and cooperatively activate the major immediate-early enhancer. J. Virol. 78:9512-9523.
19. Borysiewicz LK, Hickling JK, Graham S, Sinclair J, Cranage MP, Smith GL, Sissons JG. 1988. Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J. Exp. Med. 168:919 -931.
20. Kern F, Surel IP, Faulhaber N, Frömmel C, Schneider-Mergener J, Schonemann C, Reinke P, Volk HD. 1999. Target structures of the CD8+-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J. Virol. 73:8179-8184.
21. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, Nelson JA, Picker LJ. 2005. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202:673- 685.
22. Biegalke BJ. 1995. Regulation of human cytomegalovirus US3 gene transcription by a cis-repressive sequence. J. Virol. 69:5362-5367.
23. Chan YJ, Tseng WP, Hayward GS. 1996. Two distinct upstream regulatory domains containing multicopy cellular transcription factor binding sites provide basal repression and inducible enhancer characteristics to the immediate-early IES (US3) promoter from human cytomegalovirus. J. Virol. 70:5312-5328.
24. Jones TR, Wiertz EJ, Sun L, Fish KN, Nelson JA, Ploegh HL. 1996. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc. Natl. Acad. Sci. U. S. A. 93:11327-11333.
25. Thrower AR, Bullock GC, Bissell JE, Stinski MF. 1996. Regulation of a human cytomegalovirus immediate-early gene (US3) by a silencerenhancer combination. J. Virol. 70:91-100.
26. Weston K. 1988. An enhancer element in the short unique region of human cytomegalovirus regulates the production of a group of abundant immediate early transcripts. Virology 162:406-416.
27. Hesse J, Ameres S, Besold K, Krauter S, Moosmann A, Plachter B. 2013. Suppression of CD8+ T cell recognition in the immediate-early phase of human cytomegalovirus infection. J. Gen. Virol. 94:376 -386.
28. Kalejta RF. 2008. Functions of human cytomegalovirus tegument proteins prior to immediate early gene expression. Curr. Top. Microbiol. Immunol. 325:101-115.
29. Yu D, Smith GA, Enquist LW, Shenk T. 2002. Construction of a selfexcisable bacterial artificial chromosome containing the human cytomegalovirus genome and mutagenesis of the diploid TRL/IRL13 gene. J. Virol. 76:2316 -2328.
30. Hobom U, Brune W, Messerle M, Hahn G, Koszinowski UH. 2000. Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes. J. Virol. 74:7720 -7729.
31. Schmolke S, Kern HF, Drescher P, Jahn G, Plachter B. 1995. The dominant phosphoprotein pp65 (UL83) of human cytomegalovirus is dispensable for growth in cell culture. J. Virol. 69:5959 -5968.
32. Tavalai N, Kraiger M, Kaiser N, Stamminger T. 2008. Insertion of an EYFP-pp71 (UL82) coding sequence into the human cytomegalovirus genome results in a recombinant virus with enhanced viral growth. J. Virol. 82:10543-10555.
33. Lee EC, Yu D, Martinez de Velasco J, Tessarollo L, Swing DA, Court DL, Jenkins NA, Copeland NG. 2001. A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics 73:56-65.
34. Rose RE. 1988. The nucleotide sequence of pACYC184. Nucleic Acids Res. 16:355.
35. Cherepanov PP, Wackernagel W. 1995. Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. Gene 158:9 -14.
36. Andreoni M, Faircloth M, Vugler L, Britt WJ. 1989. A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J. Virol. Methods 23:157-167.
37. Gallez-Hawkins G, Villacres MC, Li X, Sanborn MC, Lomeli NA, Zaia JA. 2003. Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response. J. Virol. 77:4457- 4462.
38. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ. 1997. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90:1751-1767.
39. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG. 1996. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. 70: 7569-7579.
40. Irmiere A, Gibson W. 1983. Isolation and characterization of a noninfectious virion-like particle released from cells infected with human strains of cytomegalovirus. Virology 130:118 -133.
41. Wisniewski JR, Zougman A, Nagaraj N, Mann M. 2009. Universal sample preparation method for proteome analysis. Nat. Methods 6:359-362.
42. Tenzer S, Docter D, Rosfa S, Wlodarski A, Kuharev J, Rekik A, Knauer SK, Bantz C, Nawroth T, Bier C, Sirirattanapan J, Mann W, Treuel L, Zellner R, Maskos M, Schild H, Stauber RH. 2011. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano. 5:7155-7167.
43. Geromanos SJ, Vissers JP, Silva JC, Dorschel CA, Li GZ, Gorenstein MV, Bateman RH, Langridge JI. 2009. The detection, correlation, and comparison of peptide precursor and product ions from data independent LC-MS with data dependent LC-MS/MS. Proteomics 9:1683-1695.
44. Silva JC, Denny R, Dorschel CA, Gorenstein M, Kass IJ, Li GZ, McKenna T, Nold MJ, Richardson K, Young P, Geromanos S. 2005. Quantitative proteomic analysis by accurate mass retention time pairs. Anal. Chem. 77:2187-2200.
45. Patzig J, Jahn O, Tenzer S, Wichert SP, de Monasterio-Schrader P, Rosfa S, Kuharev J, Yan K, Bormuth I, Bremer J, Aguzzi A, Orfaniotou F, Hesse D, Schwab MH, Mobius W, Nave KA, Werner HB. 2011. Quantitative and integrative proteome analysis of peripheral nerve myelin identifies novel myelin proteins and candidate neuropathy loci. J. Neurosci. 31:16369-16386.
46. Bradshaw RA, Burlingame AL, Carr S, Aebersold R. 2006. Reporting protein identification data: the next generation of guidelines. Mol. Cell. Proteomics 5:787-788.
47. Taylor RT, Bresnahan WA. 2006. Human cytomegalovirus immediateearly 2 protein IE86 blocks virus-induced chemokine expression. J. Virol. 80:920 -928.
48. Rüger B, Klages S, Walla B, Albrecht J, Fleckenstein B, Tomlinson P, Barrell B. 1987. Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus. J. Virol. 61:446-453.
49. Besold K, Plachter B. 2008. Recombinant viruses as tools to study human cytomegalovirus immune modulation. Med. Microbiol. Immunol. 197: 215-222.
50. Lukashchuk V, McFarlane S, Everett RD, Preston CM. 2008. Human cytomegalovirus protein pp71 displaces the chromatin-associated factor ATRX from nuclear domain 10 at early stages of infection. J. Virol. 82: 12543-12554.
51. Tavalai N, Papior P, Rechter S, Stamminger T. 2008. Nuclear domain 10 components promyelocytic leukemia protein and hDaxx independently contribute to an intrinsic antiviral defense against human cytomegalovirus infection. J. Virol. 82:126 -137.
52. Gilbert MJ, Riddell SR, Li CR, Greenberg PD. 1993. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J. Virol. 67:3461-3469.
53. Abate DA, Watanabe S, Mocarski ES. 2004. Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J. Virol. 78:10995-11006.
54. Browne EP, Shenk T. 2003. Human cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells. Proc. Natl. Acad. Sci. U. S. A. 100:11439 -11444.
55. Barel MT, Pizzato N, Le Bouteiller P, Wiertz EJ, Lenfant F. 2006. Subtle sequence variation among MHC class I locus products greatly influences sensitivity to HCMV US2- and US11-mediated degradation. Int. Immunol. 18:173-182.
56. Llano M, Guma M, Ortega M, Angulo A, Lopez-Botet M. 2003. Differential effects of US2, US6 and US11 human cytomegalovirus proteins on HLA class Ia and HLA-E expression: impact on target susceptibility to NK cell subsets. Eur. J. Immunol. 33:2744 -2754.
57. Park B, Kim Y, Shin J, Lee S, Cho K, Früh K, Lee S, Ahn K. 2004. Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. Immunity 20:71- 85.
58. Thilo C, Berglund P, Applequist SE, Yewdell JW, Ljunggren HG, Achour A. 2006. Dissection of the interaction of the human cytomegalovirus- derived US2 protein with major histocompatibility complex class I molecules: prominent role of a single arginine residue in human leukocyte antigen-A2. J. Biol. Chem. 281:8950-8957.